• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.

作者信息

Mhlanga Adquate, Wasserman Ori, Lampertico Pietro, Cotler Scott J, Dahari Harel

机构信息

Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

JHEP Rep. 2024 Sep 6;7(2):101211. doi: 10.1016/j.jhepr.2024.101211. eCollection 2025 Feb.

DOI:10.1016/j.jhepr.2024.101211
PMID:39867682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11758951/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3912/11758951/916dad1756b3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3912/11758951/916dad1756b3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3912/11758951/916dad1756b3/gr1.jpg

相似文献

1
Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.基于布列韦肽治疗期间丁型肝炎病毒动力学的建模挑战
JHEP Rep. 2024 Sep 6;7(2):101211. doi: 10.1016/j.jhepr.2024.101211. eCollection 2025 Feb.
2
Bulevirtide and emerging drugs for the treatment of hepatitis D.布乐瑞韦肽与治疗丁型肝炎的新兴药物。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1245-1253. doi: 10.1080/14712598.2023.2273260. Epub 2023 Dec 28.
3
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.布列韦肽联合替诺福韦酯治疗乙型肝炎病毒和丁型肝炎病毒合并感染患者的安全性和有效性（MYR202）：一项多中心、随机、平行组、开放标签的2期试验。
Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13.
4
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.回复：基于布列韦肽治疗期间丁型肝炎病毒动力学的建模挑战
JHEP Rep. 2024 Nov 16;7(3):101277. doi: 10.1016/j.jhepr.2024.101277. eCollection 2025 Mar.
5
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.布列净治疗慢性丁型肝炎的临床和经济价值
Gastroenterol Hepatol. 2025 Mar;48(3):502241. doi: 10.1016/j.gastrohep.2024.502241. Epub 2024 Sep 7.
6
Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation.数学模型表明，进入抑制剂布列韦肽可能会干扰丁型肝炎病毒从循环系统中的清除。
J Hepatol. 2022 May;76(5):1229-1231. doi: 10.1016/j.jhep.2021.12.030. Epub 2022 Jan 5.
7
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.蓝病毒单药治疗慢性 HDV 患者：一项 III 期随机试验中至第 96 周的疗效和安全性结果。
J Hepatol. 2024 Oct;81(4):621-629. doi: 10.1016/j.jhep.2024.05.001. Epub 2024 May 9.
8
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.聚乙二醇干扰素对接受布列韦肽治疗的丁型肝炎病毒感染患者病毒动力学的影响。
JHEP Rep. 2024 Mar 24;6(8):101070. doi: 10.1016/j.jhepr.2024.101070. eCollection 2024 Aug.
9
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.使用布列韦肽治疗丁型肝炎——114例患者的真实世界经验。
JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr.
10
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.布乐瑞肽联合聚乙二醇干扰素治疗慢性丁型肝炎。
N Engl J Med. 2024 Jul 11;391(2):133-143. doi: 10.1056/NEJMoa2314134. Epub 2024 Jun 6.

引用本文的文献

1
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.回复：基于布列韦肽治疗期间丁型肝炎病毒动力学的建模挑战
JHEP Rep. 2024 Nov 16;7(3):101277. doi: 10.1016/j.jhepr.2024.101277. eCollection 2025 Mar.

本文引用的文献

1
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.聚乙二醇干扰素对接受布列韦肽治疗的丁型肝炎病毒感染患者病毒动力学的影响。
JHEP Rep. 2024 Mar 24;6(8):101070. doi: 10.1016/j.jhepr.2024.101070. eCollection 2024 Aug.
2
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.在进入抑制剂布列韦肽作用下对丁型肝炎病毒动力学进行建模表明存在两个丁型肝炎病毒感染的细胞群体。
JHEP Rep. 2023 Nov 15;6(2):100966. doi: 10.1016/j.jhepr.2023.100966. eCollection 2024 Feb.
3
Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation.
数学模型表明，进入抑制剂布列韦肽可能会干扰丁型肝炎病毒从循环系统中的清除。
J Hepatol. 2022 May;76(5):1229-1231. doi: 10.1016/j.jhep.2021.12.030. Epub 2022 Jan 5.
4
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.使用洛那法尼进行口服异戊二烯化抑制治疗慢性丁型肝炎感染：一项概念验证性随机、双盲、安慰剂对照的2A期试验。
Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16.
5
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.丙型肝炎病毒动力学建模：肝脏再生与关键药物疗效
J Theor Biol. 2007 Jul 21;247(2):371-81. doi: 10.1016/j.jtbi.2007.03.006. Epub 2007 Mar 14.
6
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.丙型肝炎病毒的体内动态及α干扰素治疗的抗病毒疗效。
Science. 1998 Oct 2;282(5386):103-7. doi: 10.1126/science.282.5386.103.